Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2017

01-08-2017 | Correspondence

Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis

Authors: E. Rodríguez-Lomba, I. Marquez-Rodas, E. Mercader-Cidoncha, R. Suárez-Fernández, J. A. Avilés-Izquierdo

Published in: Clinical and Translational Oncology | Issue 8/2017

Login to get access

Excerpt

Although tumor thickness has proven to be the strongest predictor for disease-free and overall survival in patients with primary cutaneous melanoma, it has been noted that not all patients with thick melanoma (>4 mm tumor thickness) die from disease progression . To this date, few studies regarding the epidemiological features of patients with thick melanoma have been reported [1]. Our knowledge on which factors, besides tumor thickness, are responsible for the differences in these patients’ prognosis is currently limited. …
Literature
1.
Grange F, Barbe C, Aubin F, Lipsker D, Granel-Brocard F, Velten M, et al. Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France. Arch Dermatol. 2012;148:1370–6.CrossRef
2.
Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P. Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. J Am Acad Dermatol. 2016;75:967–74.CrossRef
3.
Joosse A, Collete S, Suciu S, Nijsten T, Patel PM, Keilholz U, et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survical in metastasized stage III to IV melanoma: a pooled analysis of five European organization for research and treatment of cancer randomized controlled trials. J Clin Oncol. 2013;31:2337–46.CrossRef
4.
Avilés-Izquierdo JA, Lázaro-Ochaita P. Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. Clin Transl Oncol. 2012;14:237–40.CrossRef
5.
Bello DM, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, et al. The prognostic significance of sentinel lymph node status for patients with thick melanoma. Ann Surg Oncol. 2016;23:938–45.CrossRef
Metadata
Title
Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis
Authors
E. Rodríguez-Lomba
I. Marquez-Rodas
E. Mercader-Cidoncha
R. Suárez-Fernández
J. A. Avilés-Izquierdo
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1637-y

Other articles of this Issue 8/2017

Clinical and Translational Oncology 8/2017 Go to the issue

Research Article

Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy

Research Article

Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer

Research Article

Long noncoding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis

Research Article

BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines

Research Article

The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis

Research Article

Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits